Bayer AG Faces Significant Challenges

German pharmaceutical giant Bayer AG witnessed a sharp decline in its stock value, dropping over 5% this Wednesday. This downturn came after the company announced a 3.6% year-over-year decrease in sales for the second quarter of fiscal 2025, totaling €10.7 billion. Additionally, Bayer disclosed the elimination of approximately 1,300 jobs in the last quarter, bringing the total layoffs since the first quarter of fiscal 2023 to a staggering 12,179. By the end of Q2 2025, Bayer's workforce was reduced to 89,556 employees.

Investors Brace for Impact

The market's reaction was further compounded by anticipation of upcoming tariffs on pharmaceutical products by United States President Donald Trump. Trump hinted at an imminent announcement, stating the details would be revealed "very soon." This uncertainty added to the pressure on Bayer's stock, which fell by 5.03% to €26.330 by 9:50 am CET following the report's release.